"Probiotics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Live microbial DIETARY SUPPLEMENTS which beneficially affect the host animal by improving its intestinal microbial balance. Antibiotics and other related compounds are not included in this definition. In humans, lactobacilli are commonly used as probiotics, either as single species or in mixed culture with other bacteria. Other genera that have been used are bifidobacteria and streptococci. (J. Nutr. 1995;125:1401-12)
| Descriptor ID |
D019936
|
| MeSH Number(s) |
G07.203.300.456.500 J02.500.456.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Probiotics".
Below are MeSH descriptors whose meaning is more specific than "Probiotics".
This graph shows the total number of publications written about "Probiotics" by people in this website by year, and whether "Probiotics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 1 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 6 | 1 | 7 |
| 2010 | 5 | 1 | 6 |
| 2011 | 1 | 0 | 1 |
| 2012 | 7 | 5 | 12 |
| 2013 | 4 | 2 | 6 |
| 2014 | 6 | 5 | 11 |
| 2015 | 5 | 2 | 7 |
| 2016 | 5 | 2 | 7 |
| 2017 | 3 | 4 | 7 |
| 2018 | 3 | 3 | 6 |
| 2019 | 6 | 3 | 9 |
| 2020 | 10 | 4 | 14 |
| 2021 | 6 | 1 | 7 |
| 2022 | 5 | 0 | 5 |
| 2023 | 10 | 0 | 10 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 3 | 5 |
| 2026 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Probiotics" by people in Profiles.
-
Limosilactobacillus reuteri promotes melatonin release from human intestinal organoids via 5'ectonucleotidase activity. Gut Microbes. 2026 Dec 31; 18(1):2670854.
-
When probiotics guidelines differ: a practical guide for clinicians and researchers. Gut Microbes. 2026 Dec 31; 18(1):2657049.
-
Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection. Cancer Med. 2026 Apr; 15(4):e71738.
-
Limosilactobacillus reuteri alleviates proinflammatory T-cell-mediated liver injury and transcriptomic changes in immunocompromised mice. Front Immunol. 2026; 17:1713120.
-
Comparing various bowel preparation regimens in constipated patients undergoing colonoscopy: A systematic review and network meta-analysis of randomised controlled trials. Colorectal Dis. 2026 Feb; 28(2):e70399.
-
Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults. Helicobacter. 2025 Sep-Oct; 30(5):e70064.
-
Limosilactobacillus reuteri enables oral-to-systemic absorption of iberiotoxin for treatment of collagen-induced arthritis in rats. Microb Cell Fact. 2025 Aug 02; 24(1):177.
-
Present and future of microbiome-targeting therapeutics. J Clin Invest. 2025 Jun 02; 135(11).
-
Microbiome-Based Therapeutics for Salt-Sensitive Hypertension: A Scoping Review. Nutrients. 2025 Feb 27; 17(5).
-
New approaches in childhood IgE-mediated food allergy treatment. Curr Opin Allergy Clin Immunol. 2025 Apr 01; 25(2):115-122.